About Me
I’m a PhD student at the Department of Clinical Neuroscience, Karolinska Institutet, Sweden. My research is focused on pharmacoepidemiological studies of disease modifying therapies for multiple sclerosis.
Articles
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
Annals of Neurology (2020), DOI: 10/ggk2dq
P. Alping, J. Askling, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, and T. Frisell
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurology (2019), DOI: 10/ggk2dr
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, and T. Frisell
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
Epidemiology (2019), DOI: 10/gfvpd7
P. Alping, F. Piehl, A. Langer-Gould, T. Frisell, and the COMBAT-MS Study Group
Rituximab in Multiple Sclerosis: A Retrospective Observational Study on Safety and Efficacy
Neurology (2016), DOI: 10.1212/WNL.0000000000003331
J. Salzer, R. Svenningsson, P. Alping, L. Novakova, A. Björck, K. Fink, P. Islam-Jakobsson, C. Malmeström, M. Axelsson, M. Vågberg, P. Sundström, J. Lycke, F. Piehl, and A. Svenningsson
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Annals of Neurology (2016), DOI: 10.1002/ana.24651
P. Alping, T. Frisell, L. Novakova, P. Islam-Jakobsson, J. Salzer, A. Björck, M. Axelsson, C. Malmeström, K. Fink, J. Lycke, A. Svenningsson, and F. Piehl
Conferences
Cancer Risk among Swedish Multiple Sclerosis Patients: A Nationwide Cohort Study Comparing Rituximab, Fingolimod, and Natalizumab
ECTRIMS 2018, Berlin, Germany—Oral presentation
P. Alping, F. Piehl, and T. Frisell
Baseline Characteristics from the COMBAT-MS Study: Initial Analyses Suggest Main Driver for Therapy Choice Is Geographic Location
ECTRIMS 2017, Paris, France—Poster
P. Alping, J. Burman, K. Fink, M. Gunnarsson, J. Lycke, P. Nilsson, J. Salzer, M. Vrethem, A. Langer-Gould, A. Svenningsson, T. Frisell, and F. Piehl
Projects
KEP Code Club - Programming seminars for researchers
Snakemake Language - VSCode extension for Snakemake
Graphical Study Design - Graphical depictions of study designs
SAS to CSV - Tool converting .sas7bdat files to .csv files
sascli.cmd - Run SAS scripts with more generous exit codes
Example project using Git and Snakemake